NCT04446065 (HERD) is a Phase 2, PHASE3 clinical trial of Previfenon® in COVID-19, sponsored by MELISA Institute Genomics & Proteomics Research SpA.

Who is sponsoring NCT04446065?

NCT04446065 is sponsored by MELISA Institute Genomics & Proteomics Research SpA.

What drugs are being tested in NCT04446065?

Interventions in NCT04446065: Previfenon®, Placebo.

What condition does NCT04446065 study?

NCT04446065 studies COVID-19, SARS-CoV2.

Is NCT04446065 still recruiting?

NCT04446065 is currently status unknown. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT04446065: HERD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers

Status unknown Phase 2, PHASE3 Last updated 9 September 2020

What this trial tests

Phase 2, PHASE3 trial testing Previfenon® in COVID-19 in 524 participants. Status unknown.

Timeline

30 September 2020

Primary endpoint
30 September 2021

30 October 2021

Quick facts

Lead sponsor	MELISA Institute Genomics & Proteomics Research SpA
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	524
Start date	30 September 2020
Primary completion	30 September 2021
Estimated completion	30 October 2021

Drugs / interventions tested

Previfenon® — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV2 — all drugs for SARS-CoV2 →

Sponsor

MELISA Institute Genomics & Proteomics Research SpA

Who can join

25 and older, any sex, with COVID-19 or SARS-CoV2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, et al · · 2022 · cited 74× · PMID 36464706 · DOI 10.1038/s41392-022-01249-8
Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor.
Liu J, Bodnar BH, Meng F, Khan AI, et al · · 2021 · cited 64× · PMID 34461999 · DOI 10.1186/s13578-021-00680-8
Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.
Majnooni MB, Fakhri S, Shokoohinia Y, Kiyani N, et al · · 2020 · cited 24× · PMID 33658931 · DOI 10.3389/fphar.2020.588467
Possible Therapeutic Use of Natural Compounds Against COVID-19.
Khan N, Chen X, Geiger JD. · · 2021 · cited 23× · PMID 33768214 · DOI 10.33696/signaling.2.036
Natural Polyphenols as Immunomodulators to Rescue Immune Response Homeostasis: Quercetin as a Research Model against Severe COVID-19.
Bernini R, Velotti F. · · 2021 · cited 20× · PMID 34641348 · DOI 10.3390/molecules26195803
A Comprehensive Summary of the Knowledge on COVID-19 Treatment.
Peng Y, Tao H, Satyanarayanan SK, Jin K, et al · · 2021 · cited 18× · PMID 33532135 · DOI 10.14336/ad.2020.1124
COVID-19 Therapeutic Potential of Natural Products.
Low Z, Lani R, Tiong V, Poh C, et al · · 2023 · cited 15× · PMID 37298539 · DOI 10.3390/ijms24119589
Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention.
Gligorijevic N, Radomirovic M, Nedic O, Stojadinovic M, et al · · 2021 · cited 14× · PMID 34830267 · DOI 10.3390/ijms222212385

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04446065 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MELISA Institute Genomics & Proteomics Research SpA
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04446065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing